serenase 2 mg/ml oral opløsning
essential pharma limited - haloperidol - oral opløsning - 2 mg/ml
serenase 5 mg tabletter
essential pharma limited - haloperidol - tabletter - 5 mg
serenase dekanoat 100 mg/ml injektionsvæske, opløsning
essential pharma limited - haloperidoldecanoat - injektionsvæske, opløsning - 100 mg/ml
serenase dekanoat 50 mg/ml injektionsvæske, opløsning
essential pharma limited - haloperidol - injektionsvæske, opløsning - 50 mg/ml
klacid sr 500 mg depottabletter
paranova danmark a/s - clarithromycin - depottabletter - 500 mg
plaquenil 200 mg filmovertrukne tabletter
paranova danmark a/s - hydroxychloroquinsulfat - filmovertrukne tabletter - 200 mg
warfarinnatrium "2care4" 2,5 mg tabletter
2care4 aps - warfarinnatrium - tabletter - 2,5 mg
xospata
astellas pharma europe b.v. - gilteritinib fumarate - leukæmi, myeloid, akut - antineoplastiske midler - xospata er angivet som monoterapi til behandling af voksne patienter med recidiverende eller refraktær akut myeloid leukæmi (aml) med en mutation flt3.
droperidol "sintetica" 0,5 mg/ml injektionsvæske, opløsning
sintetica gmbh - droperidol - injektionsvæske, opløsning - 0,5 mg/ml
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.